NYSE:EBS - Emergent BioSolutions Stock Price, Price Target & More

$52.28 -2.24 (-4.11 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$54.52
Today's Range$51.24 - $53.03
52-Week Range$28.85 - $55.91
Volume292,520 shs
Average Volume360,284 shs
Market Capitalization$2.70 billion
P/E Ratio28.69
Dividend YieldN/A
Beta1.29

About Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions logoEmergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.85%
Quick Ratio3.42%

Price-To-Earnings

Trailing P/E Ratio28.69
Forward P/E Ratio22.44
P/E Growth1.06

Sales & Book Value

Annual Sales$560.87 million
Price / Sales4.61
Cash Flow$2.6810 per share
Price / Cash19.50
Book Value$18.47 per share
Price / Book2.83

Profitability

EPS (Most Recent Fiscal Year)$1.90
Net Income$82.59 million
Net Margins14.73%
Return on Equity13.66%
Return on Assets9.54%

Miscellaneous

Employees1,256
Outstanding Shares49,490,000

How to Become a New Pot Stock Millionaire

Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How will Emergent BioSolutions' stock buyback program work?

Emergent BioSolutions announced that its Board of Directors has approved a stock buyback plan on Friday, March 23rd 2018, which authorizes the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions (NYSE:EBS) announced its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.70 by $0.04. The biopharmaceutical company earned $193.80 million during the quarter, compared to the consensus estimate of $189.96 million. Emergent BioSolutions had a net margin of 14.73% and a return on equity of 13.66%. Emergent BioSolutions's revenue for the quarter was up 27.8% on a year-over-year basis. During the same period last year, the company posted $0.74 EPS. View Emergent BioSolutions' Earnings History.

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Emergent BioSolutions.

What price target have analysts set for EBS?

4 analysts have issued twelve-month target prices for Emergent BioSolutions' stock. Their predictions range from $53.00 to $60.00. On average, they expect Emergent BioSolutions' share price to reach $56.00 in the next year. View Analyst Ratings for Emergent BioSolutions.

Who are some of Emergent BioSolutions' key competitors?

Who are Emergent BioSolutions' key executives?

Emergent BioSolutions' management team includes the folowing people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)
  • Mr. Daniel J. Abdun-Nabi, Pres, CEO & Director (Age 63)
  • Mr. Robert G. Kramer Sr., Exec. VP of Admin., CFO, Treasurer & Principal Accounting Officer (Age 61)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations and Pres of Biodefense Division (Age 47)
  • Dr. W. James Jackson, Sr. VP & Chief Scientific Officer (Age 63)

Has Emergent BioSolutions been receiving favorable news coverage?

Media headlines about EBS stock have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Emergent BioSolutions earned a news impact score of 0.05 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.60 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Emergent BioSolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $52.28.

How big of a company is Emergent BioSolutions?

Emergent BioSolutions has a market capitalization of $2.70 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent BioSolutions employs 1,256 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]


MarketBeat Community Rating for Emergent BioSolutions (EBS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about Emergent BioSolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Emergent BioSolutions (NYSE:EBS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Emergent BioSolutions in the last 12 months. Their average twelve-month price target is $56.00, suggesting that the stock has a possible upside of 7.12%. The high price target for EBS is $60.00 and the low price target for EBS is $53.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.752.672.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.00$52.75$50.3333$45.00
Price Target Upside: 7.12% upside6.27% upside0.96% downside11.25% upside

Emergent BioSolutions (NYSE:EBS) Consensus Price Target History

Price Target History for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2018Wells FargoReiterated RatingOutperform -> Market PerformHighView Rating Details
2/27/2018Singular ResearchBoost Price TargetBuy -> Buy$45.00 -> $60.00MediumView Rating Details
1/24/2018Goldman SachsInitiated CoverageNeutral -> Neutral$55.00LowView Rating Details
1/16/2018Chardan CapitalBoost Price TargetBuy$47.00 -> $53.00MediumView Rating Details
1/9/2017CowenReiterated RatingHoldN/AView Rating Details
8/5/2016JPMorgan ChaseLower Price TargetOverweight$45.00 -> $36.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Emergent BioSolutions (NYSE:EBS) Earnings History and Estimates Chart

Earnings by Quarter for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS) Earnings Estimates

Current Year EPS Consensus Estimate: $2.33 EPS
Next Year EPS Consensus Estimate: $3.03 EPS

Emergent BioSolutions (NYSE EBS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018$0.37N/AView Earnings Details
2/22/2018Q4 2017$0.70$0.74$189.96 million$193.80 millionViewListenView Earnings Details
11/2/2017Q3 2017$0.41$0.73$124.55 million$149.43 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.26$0.13$111.57 million$100.77 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.31$0.23$121.30 million$116.90 millionViewListenView Earnings Details
2/23/2017Q4 2016$0.48$0.74$120.45 million$151.66 millionViewListenView Earnings Details
11/7/2016Q3$0.26$0.58$112.30 million$142.91 millionViewListenView Earnings Details
8/4/2016Q2($0.17)($0.18)$111.20 million$101.49 millionViewListenView Earnings Details
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details
2/25/2016Q4$0.69$0.78$168.07 million$168.10 millionViewListenView Earnings Details
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details
5/7/2015Q1($0.46)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details
3/5/2015Q115$0.97$0.75$147.00 million$148.00 millionViewListenView Earnings Details
11/6/2014Q414$0.37$0.67$126.90 million$138.00 millionViewListenView Earnings Details
8/7/2014Q214$0.26$0.24$109.25 million$110.30 millionViewListenView Earnings Details
5/8/2014Q114($0.34)($0.40)$57.30 million$53.90 millionViewListenView Earnings Details
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details
8/2/2012$0.21$0.21ViewN/AView Earnings Details
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details
3/8/2012$0.72$0.78ViewN/AView Earnings Details
11/3/2011($0.04)$0.04ViewN/AView Earnings Details
8/4/2011$0.33$0.40ViewN/AView Earnings Details
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details
3/10/2011$0.67$0.76ViewN/AView Earnings Details
11/4/2010Q3 2010$0.53$0.41ViewN/AView Earnings Details
8/5/2010Q2 2010$0.26$0.31ViewN/AView Earnings Details
5/5/2010Q1 2010$0.17$0.08ViewN/AView Earnings Details
3/4/2010Q4 2009$0.05$0.13ViewN/AView Earnings Details
11/5/2009Q3 2009$0.06$0.03ViewN/AView Earnings Details
8/6/2009Q2 2009$0.30$0.55ViewN/AView Earnings Details
5/7/2009Q1 2009$0.15$0.35ViewN/AView Earnings Details
3/5/2009Q4 2008$0.06$0.05ViewN/AView Earnings Details
11/6/2008Q3 2008$0.17$0.34ViewN/AView Earnings Details
8/7/2008Q2 2008$0.19$0.06ViewN/AView Earnings Details
5/7/2008Q1 2008$0.27$0.24ViewN/AView Earnings Details
3/7/2008Q4 2007$0.87$0.93ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Emergent BioSolutions (NYSE:EBS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Emergent BioSolutions (NYSE EBS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 82.29%
Insider Trading History for Emergent BioSolutions (NYSE:EBS)
Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE EBS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Ronald RichardDirectorSell7,893$55.00$434,115.0031,303View SEC Filing  
3/12/2018Adam HaveyEVPSell5,842$52.82$308,574.4435,756View SEC Filing  
3/1/2018Adam HaveyEVPSell1,898$49.50$93,951.00View SEC Filing  
1/22/2018Jerome M HauerDirectorSell5,152$50.91$262,288.3223,797View SEC Filing  
1/2/2018Daniel Abdun-NabiCEOSell21,906$47.91$1,049,516.46226,040View SEC Filing  
12/13/2017Daniel Abdun-NabiCEOSell20,000$45.99$919,800.00224,134View SEC Filing  
12/12/2017Ronald RichardDirectorSell23,681$45.02$1,066,118.6247,091View SEC Filing  
12/7/2017Zsolt HarsanyiDirectorSell7,000$42.47$297,290.0037,077View SEC Filing  
11/29/2017Fuad El-HibriChairmanSell47,983$41.88$2,009,528.041,550,216View SEC Filing  
11/14/2017Fuad El-HibriChairmanSell40,000$40.37$1,614,800.00View SEC Filing  
11/7/2017George A JoulwanDirectorSell14,251$41.24$587,711.2434,323View SEC Filing  
11/3/2017Daniel Abdun-NabiCEOSell31,508$42.77$1,347,597.16215,642View SEC Filing  
9/29/2017Fuad El-HibriChairmanSell25,000$40.50$1,012,500.001,555,216View SEC Filing  
9/28/2017Ronald RichardDirectorSell22,415$40.00$896,600.0024,676View SEC Filing  
9/27/2017Adam HaveyEVPSell7,885$39.50$311,457.5033,931View SEC Filing  
9/27/2017Daniel Abdun-NabiCEOSell15,000$39.92$598,800.00219,134View SEC Filing  
9/27/2017Fuad El-HibriChairmanSell25,000$39.50$987,500.001,555,216View SEC Filing  
9/27/2017Ronald RichardDirectorSell1,266$40.00$50,640.0024,676View SEC Filing  
9/14/2017Fuad El-HibriChairmanSell25,000$38.50$962,500.001,603,763View SEC Filing  
9/8/2017Adam HaveyEVPSell7,885$37.06$292,218.1033,931View SEC Filing  
9/7/2017Fuad El-HibriChairmanSell16,439$37.50$616,462.501,605,216View SEC Filing  
9/5/2017Fuad El-HibriChairmanSell3,100$37.50$116,250.001,621,655View SEC Filing  
8/31/2017Daniel Abdun-NabiCEOSell15,000$37.21$558,150.00219,134View SEC Filing  
8/31/2017Fuad El-HibriChairmanSell5,461$37.50$204,787.501,624,755View SEC Filing  
8/15/2017Jerome M HauerDirectorSell10,776$35.83$386,104.0829,421View SEC Filing  
7/27/2017Fuad El-HibriChairmanSell25,000$36.50$912,500.001,630,216View SEC Filing  
7/20/2017Fuad El-HibriChairmanSell25,000$35.50$887,500.001,655,216View SEC Filing  
4/3/2017Adam HaveyEVPSell11,419$28.62$326,811.7826,046View SEC Filing  
3/8/2017Jerome M HauerDirectorSell2,576$31.27$80,551.5217,404View SEC Filing  
1/17/2017Adam HaveyEVPSell8,438$29.75$251,030.5041,424View SEC Filing  
1/17/2017Sue BaileyDirectorSell19,424$29.78$578,446.7234,637View SEC Filing  
1/10/2017Daniel Abdun-NabiInsiderSell28,240$31.28$883,347.20172,945View SEC Filing  
12/13/2016Ronald RichardDirectorSell5,900$34.09$201,131.0019,870View SEC Filing  
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.0020,785View SEC Filing  
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26170,966View SEC Filing  
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.501,649,073View SEC Filing  
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.671,698,667View SEC Filing  
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.001,719,073View SEC Filing  
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.1141,685View SEC Filing  
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.001,719,073View SEC Filing  
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.001,719,073View SEC Filing  
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00179,665View SEC Filing  
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.4820,085View SEC Filing  
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.5128,800View SEC Filing  
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.001,699,073View SEC Filing  
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.0018,800View SEC Filing  
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.2538,469View SEC Filing  
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.501,724,073View SEC Filing  
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34194,319View SEC Filing  
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.501,728,282View SEC Filing  
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.001,774,073View SEC Filing  
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.4077,551View SEC Filing  
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.2080,597View SEC Filing  
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.3291,607View SEC Filing  
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.6439,163View SEC Filing  
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.0014,100View SEC Filing  
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.0854,254View SEC Filing  
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.3743,379View SEC Filing  
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.2841,100View SEC Filing  
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.8028,500View SEC Filing  
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.0013,733View SEC Filing  
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54185,368View SEC Filing  
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.501,852,284View SEC Filing  
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.501,842,255View SEC Filing  
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.6428,558View SEC Filing  
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.501,835,268View SEC Filing  
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.001,828,493View SEC Filing  
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.501,821,943View SEC Filing  
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.6028,500View SEC Filing  
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.2662,183View SEC Filing  
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.0036,145View SEC Filing  
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.8036,920View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Emergent BioSolutions (NYSE EBS) News Headlines

Source:
DateHeadline
Emergent BioSolutions (EBS) Receives "Market Perform" Rating from Wells FargoEmergent BioSolutions (EBS) Receives "Market Perform" Rating from Wells Fargo
www.americanbankingnews.com - April 25 at 10:49 AM
Emergent BioSolutions (EBS) Lowered to Market Perform at Wells FargoEmergent BioSolutions (EBS) Lowered to Market Perform at Wells Fargo
www.americanbankingnews.com - April 24 at 9:06 PM
Emergent BioSolutions (EBS) Director Sells $434,115.00 in StockEmergent BioSolutions (EBS) Director Sells $434,115.00 in Stock
www.americanbankingnews.com - April 19 at 7:34 PM
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
finance.yahoo.com - April 19 at 8:26 AM
Emergent BioSolutions (EBS) Receives Consensus Recommendation of "Buy" from AnalystsEmergent BioSolutions (EBS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 8:41 AM
Emergent BioSolutions to enter 5 new countries with anthrax vaccineEmergent BioSolutions to enter 5 new countries with anthrax vaccine
www.bizjournals.com - April 13 at 5:23 PM
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European CountriesEmergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
finance.yahoo.com - April 12 at 8:54 AM
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European CountriesEmergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
finance.yahoo.com - April 12 at 8:54 AM
Emergent (EBS) Gains 86.1% in a Years Time: Heres WhyEmergent (EBS) Gains 86.1% in a Year's Time: Here's Why
www.msn.com - April 7 at 8:39 AM
Emergent (EBS) Gains 86.1% in a Year's Time: Here's WhyEmergent (EBS) Gains 86.1% in a Year's Time: Here's Why
finance.yahoo.com - April 7 at 8:39 AM
Emergent Biosolutions (EBS) Lifted to Strong-Buy at Zacks Investment ResearchEmergent Biosolutions (EBS) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:16 PM
Emergent Biosolutions (EBS) Rating Lowered to Hold at Zacks Investment ResearchEmergent Biosolutions (EBS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 7:37 PM
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Companys Growth ...Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth ...
globenewswire.com - March 28 at 8:39 AM
BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer
www.reuters.com - March 28 at 8:39 AM
New operating chief at Emergent BioNew operating chief at Emergent Bio
seekingalpha.com - March 26 at 5:09 PM
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth StrategyEmergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
finance.yahoo.com - March 26 at 5:09 PM
Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?
finance.yahoo.com - March 26 at 8:32 AM
Singular Research Raises Emergent Biosolutions (EBS) Price Target to $60.00Singular Research Raises Emergent Biosolutions (EBS) Price Target to $60.00
www.americanbankingnews.com - March 24 at 9:28 PM
Emergent Biosolutions Inc (EBS) Given Average Recommendation of "Buy" by AnalystsEmergent Biosolutions Inc (EBS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 24 at 8:04 AM
Emergent Biosolutions (EBS) to Buyback $50.00 million in  Outstanding SharesEmergent Biosolutions (EBS) to Buyback $50.00 million in Outstanding Shares
www.americanbankingnews.com - March 23 at 11:26 AM
Emergent BioSolutions (EBS) to Implement Stock Repurchase Program for up to $50 MillionEmergent BioSolutions (EBS) to Implement Stock Repurchase Program for up to $50 Million
www.streetinsider.com - March 22 at 5:28 PM
Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common StockEmergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
finance.yahoo.com - March 22 at 5:28 PM
Emergent BioSolutions Reaches Analyst Target Price - NasdaqEmergent BioSolutions Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - March 22 at 8:37 AM
Edited Transcript of EBS earnings conference call or presentation 22-Feb-18 10:00pm GMTEdited Transcript of EBS earnings conference call or presentation 22-Feb-18 10:00pm GMT
finance.yahoo.com - March 21 at 5:29 PM
Emergent Biosolutions Inc (EBS) EVP Adam Havey Sells 5,842 SharesEmergent Biosolutions Inc (EBS) EVP Adam Havey Sells 5,842 Shares
www.americanbankingnews.com - March 13 at 7:52 PM
Arizona State Retirement System Has $2.75 Million Stake in Emergent Biosolutions Inc (EBS)Arizona State Retirement System Has $2.75 Million Stake in Emergent Biosolutions Inc (EBS)
www.americanbankingnews.com - March 6 at 4:36 AM
Emergent Biosolutions Inc (EBS) Shares Sold by Kennedy Capital Management Inc.Emergent Biosolutions Inc (EBS) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 5 at 11:39 AM
Emergent Biosolutions (EBS) Upgraded by ValuEngine to "Buy"Emergent Biosolutions (EBS) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - March 4 at 7:48 PM
Emergent Biosolutions Inc (EBS) Shares Sold by UBS Asset Management Americas Inc.Emergent Biosolutions Inc (EBS) Shares Sold by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 3 at 9:08 AM
One Gaithersburg biotechs latest marketing push: Selling doomsday kits on Amazon - Washington Business JournalOne Gaithersburg biotech's latest marketing push: Selling doomsday kits on Amazon - Washington Business Journal
www.bizjournals.com - March 3 at 8:27 AM
Credit Agricole S A Acquires 10,000 Shares of Emergent Biosolutions Inc (EBS)Credit Agricole S A Acquires 10,000 Shares of Emergent Biosolutions Inc (EBS)
www.americanbankingnews.com - March 3 at 5:30 AM
Insider Selling: Emergent Biosolutions Inc (EBS) EVP Sells 1,898 Shares of StockInsider Selling: Emergent Biosolutions Inc (EBS) EVP Sells 1,898 Shares of Stock
www.americanbankingnews.com - March 1 at 10:28 PM
Snyder Capital Management L P Purchases 144,332 Shares of Emergent Biosolutions Inc (EBS)Snyder Capital Management L P Purchases 144,332 Shares of Emergent Biosolutions Inc (EBS)
www.americanbankingnews.com - March 1 at 7:02 PM
One Gaithersburg biotechs latest marketing push: Selling doomsday kits on AmazonOne Gaithersburg biotech's latest marketing push: Selling doomsday kits on Amazon
finance.yahoo.com - March 1 at 8:24 AM
Emergent BioSolutions Gets its Deals Done (and Expect More to Come) - Motley FoolEmergent BioSolutions Gets its Deals Done (and Expect More to Come) - Motley Fool
www.fool.com - February 28 at 8:28 AM
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program - GlobeNewswire (press release)Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program - GlobeNewswire (press release)
globenewswire.com - February 28 at 8:28 AM
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin ProgramEmergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
finance.yahoo.com - February 28 at 8:28 AM
Emergent Biosolutions Inc (EBS) Receives Consensus Rating of "Buy" from AnalystsEmergent Biosolutions Inc (EBS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 27 at 9:53 AM
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE ... - GlobeNewswire (press release)EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE ... - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:30 AM
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUSEMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
finance.yahoo.com - February 26 at 5:37 PM
Emergent BioSolutions Gets its Deals Done (and Expect More to Come)Emergent BioSolutions Gets its Deals Done (and Expect More to Come)
finance.yahoo.com - February 26 at 5:37 PM
Fuller & Thaler Asset Management Inc. Takes Position in Emergent Biosolutions Inc (EBS)Fuller & Thaler Asset Management Inc. Takes Position in Emergent Biosolutions Inc (EBS)
www.americanbankingnews.com - February 26 at 2:54 PM
Emergent Biosolutions (EBS) Stock Rating Lowered by Zacks Investment ResearchEmergent Biosolutions (EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 26 at 2:42 PM
Systematic Financial Management LP Has $1.78 Million Stake in Emergent Biosolutions Inc (EBS)Systematic Financial Management LP Has $1.78 Million Stake in Emergent Biosolutions Inc (EBS)
www.americanbankingnews.com - February 25 at 11:30 AM
$190.67 Million in Sales Expected for Emergent Biosolutions Inc (EBS) This Quarter$190.67 Million in Sales Expected for Emergent Biosolutions Inc (EBS) This Quarter
www.americanbankingnews.com - February 23 at 2:30 PM
Emergent Biosolutions beats 4Q profit forecastsEmergent Biosolutions beats 4Q profit forecasts
finance.yahoo.com - February 23 at 8:34 AM
Emergent Biosolutions (EBS) Announces Quarterly  Earnings ResultsEmergent Biosolutions (EBS) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 22 at 8:34 PM
Emergent BioSolutions (EBS) Presents At RBC Capital Markets Global Healthcare Conference - SlideshowEmergent BioSolutions (EBS) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
seekingalpha.com - February 22 at 5:30 PM
What You Must Know About Emergent BioSolutions Inc’s (NYSE:EBS) 12.20% ROEWhat You Must Know About Emergent BioSolutions Inc’s (NYSE:EBS) 12.20% ROE
finance.yahoo.com - February 22 at 5:30 PM
$0.69 Earnings Per Share Expected for Emergent Biosolutions Inc (EBS) This Quarter$0.69 Earnings Per Share Expected for Emergent Biosolutions Inc (EBS) This Quarter
www.americanbankingnews.com - February 21 at 8:46 AM

SEC Filings

Emergent BioSolutions (NYSE:EBS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Emergent BioSolutions (NYSE:EBS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Emergent BioSolutions (NYSE EBS) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.